Media About Us


  • 25 November 2016

    5 Biotech IPOs Lead The Way In 2016

    5 Biotech IPOs Lead The Way In 2016

    Don Dion / Seeking Alpha

    While the IPO market was relatively weak in 2016 overall, biopharma IPOs excelled. We have been particularly impressed with AveXis, Clearside Biomedical, Protagonist Therapeutics, Reata Pharma, and bluebird bio. We plan to initiate or build on existing long positions in these companies heading into 2017.

  • 23 November 2016

    Sun Pharma moves on Russia with deal for control of JSC Biosintez

    Sun Pharma moves on Russia with deal for control of JSC Biosintez

    Eric Palmer / Fierce Pharma

    India’s Sun Pharma is joining the growing number of companies snagging a portfolio and local manufacturing in Russia with a deal worth $60 million to buy control of a Russian drug producer. Pfizer last summer announced its third deal in Russia to establish local manufacturing. It and Russia’s NovaMedica are building a manufacturing plant in the Kaluga region which they say will be producing drugs by 2020. 

  • 28 October 2016

    Corneal Inlays Better Than Monovision, Researchers Say

    Corneal Inlays Better Than Monovision, Researchers Say

    Marcia Frellick / MedScape

    One of the biggest misperceptions about corneal inlays is that the end result is monovision, experts said here at the American Academy of Ophthalmology (AAO) 2016 Annual Meeting. This is not true, according to Greg Parkhurst, MD, chief executive officer of Parkhurst NuVision in San Antonio, Texas, who is a principal investigator on clinical trials of the Raindrop Near Vision Inlay (ReVision Optics).

  • 19 October 2016

    Chairman highlights 2016 industry highlights at OIS

    Chairman highlights 2016 industry highlights at OIS

    Healio

    The past year has seen a number of important approvals and promising study progress in both biotechnology and ophthalmic devices, Emmett T. Cunningham Jr., MD, PhD, MPH, told the more than 900 attendees at the Ophthalmology Innovation Summit in his “Chairman’s 2016 Year in Review.”

  • 19 October 2016

    Liquid biopsy open database created under Cancer Moonshot, as pharma joins the fray

    Liquid biopsy open database created under Cancer Moonshot, as pharma joins the fray

    Stacy Lawrence / Fierce Biotech

    Twenty stakeholders, including major biopharmas, diagnostic players and academic institutions, have committed to creating what they expect will be the largest liquid biopsy open database for cancer genomic profiling data. It’s part of the broader ongoing Cancer Moonshot effort led by U.S. Vice President Joe Biden.

  • 19 October 2016

    White House To Announce Big Push For Cancer Blood Tests

    White House To Announce Big Push For Cancer Blood Tests

    Matthew Herper / Forbes

    The White House, as part of the Cancer Moonshot effort being run by Vice President Joe Biden, is announcing a major push to develop blood tests that can detect and monitor cancer, that aims to unite makers of diagnostic tests, drugs, and other cancer-related products.

  • 18 October 2016

    Brian Dovey: Devices are less profitable investment targets than medicines

    Brian Dovey: Devices are less profitable investment targets than medicines

    Elena Krauzova / Forbes

    Does Russia have a chance to develop biotechnology, how innovation in biomedicine is born and how cure for cancer is developed? All this and many other things  was covered in Forbes interview with Brian Dovey, managing partner of venture fund Domain Associates, one of the founders and member of the Board of Directors of the Russian pharmaceutical company "NovaMedica".

  • 14 October 2016

    Biotech IPOs slow in Q3 despite improvement in general markets

    Biotech IPOs slow in Q3 despite improvement in general markets

    Peter Winter / BioWorld

    Biotech IPOs were sluggish in the third quarter, with only seven companies successfully completing their offerings on U.S. exchanges, raising a collective $396 million in the process, according to BioWorld analysis. That was 42 percent below the 12 biotech IPOs, raising $1.35 billion in the third quarter last year and 36 percent off the 11 companies completing their offerings in the second quarter this year, raising $564 million. 

  • 05 October 2016

    Raindrop Receives FDA Approval

    Raindrop Receives FDA Approval

    Maria Scott, MD / Ophthalmology Management

    This year, I celebrated my20th anniversary of laser vision correction. I first needed glasses for myopia when I was 12, but only wore them in emergencies because I didn't want to look “nerdy.” At age 16, I got gas permeable lenses, which I loved, and later, laser vision correction, because I hated wearing glasses.

  • 27 September 2016

    Two New Corneal Inlays Increase Options for Presbyopia

    Two New Corneal Inlays Increase Options for Presbyopia

    Roger F. Steinert, MD / MedScape

    Until recently, the go-to options for treating presbyopia were reading glasses, monovision with either a contact lens or laser vision correction, or multifocal intraocular lenses. Today we now have one more arrow in our quiver: the corneal inlay, which offers patients a safe, less invasive, and reversible alternative to laser vision correction and intraocular lenses.